These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 38868900)

  • 1. Changes in Transient Elastography with Glucagon-Like Peptide-1 Receptor Agonist Use in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Real-World Retrospective Analysis.
    Akhverdyan N; Wieland A; Sullivan S; Lindsay M; Swartwood S; Arndt G; Kaizer LK; Jensen T
    Metab Syndr Relat Disord; 2024 Oct; 22(8):608-618. PubMed ID: 38868900
    [No Abstract]   [Full Text] [Related]  

  • 2. Favorable liver and skeletal muscle changes in patients with MASLD and T2DM receiving glucagon-like peptide-1 receptor agonist: A prospective cohort study.
    Kakegawa T; Sugimoto K; Saito K; Yunaiyama D; Araki Y; Wada T; Takahashi H; Yoshimasu Y; Takeuchi H; Itoi T
    Medicine (Baltimore); 2024 Jun; 103(23):e38444. PubMed ID: 38847728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A combination of non-invasive tests for the detection of significant fibrosis in patients with metabolic dysfunction-associated steatotic liver disease is not superior to magnetic resonance elastography alone.
    Duman S; Kuru D; Gumussoy M; Kiremitci S; Gokcan H; Ulas B; Ellik Z; Ozercan M; Er RE; Karakaya F; Bodakci E; Erden A; Elhan AH; Savas B; Loomba R; Idilman R
    Eur Radiol; 2024 Jun; 34(6):3882-3888. PubMed ID: 37987833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Feasibility of Fibroscan in Assessment of Hepatic Steatosis and Fibrosis in Obese Patients: Report From a General Internal Medicine Clinic.
    Avcu A; Kaya E; Yilmaz Y
    Turk J Gastroenterol; 2021 May; 32(5):466-472. PubMed ID: 34231477
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapid improvement of hepatic steatosis and liver stiffness after metabolic/bariatric surgery: a prospective study.
    Nixdorf L; Hartl L; Ströhl S; Felsenreich DM; Mairinger M; Jedamzik J; Richwien P; Mozayani B; Semmler G; Balcar L; Schwarz M; Jachs M; Dominik N; Bichler C; Trauner M; Mandorfer M; Reiberger T; Langer FB; Bauer DJM; Prager G
    Sci Rep; 2024 Jul; 14(1):17558. PubMed ID: 39080285
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination Therapy of Endoscopic Gastric Remodeling with GLP-1RA for the Treatment of MASLD.
    Jirapinyo P; Jaroenlapnopparat A; Zucker SD; Thompson CC
    Obes Surg; 2024 May; 34(5):1471-1478. PubMed ID: 38512644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vibration-Controlled Transient Elastography Scores to Predict Liver-Related Events in Steatotic Liver Disease.
    Lin H; Lee HW; Yip TC; Tsochatzis E; Petta S; Bugianesi E; Yoneda M; Zheng MH; Hagström H; Boursier J; Calleja JL; Goh GB; Chan WK; Gallego-Durán R; Sanyal AJ; de Lédinghen V; Newsome PN; Fan JG; Castéra L; Lai M; Harrison SA; Fournier-Poizat C; Wong GL; Pennisi G; Armandi A; Nakajima A; Liu WY; Shang Y; de Saint-Loup M; Llop E; Teh KK; Lara-Romero C; Asgharpour A; Mahgoub S; Chan MS; Canivet CM; Romero-Gomez M; Kim SU; Wong VW;
    JAMA; 2024 Apr; 331(15):1287-1297. PubMed ID: 38512249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence and predictive features of metabolic dysfunction-associated steatotic liver disease in type 1 diabetes.
    Fuhri Snethlage CM; Meijnikman AS; Mak AL; Rampanelli E; Voermans B; Callender CAK; de Groen P; Roep BO; van Raalte DH; Knop FK; Holleboom AG; Nieuwdorp M; Hanssen NMJ
    Eur J Endocrinol; 2024 May; 190(5):391-400. PubMed ID: 38679966
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glucagon-like peptide 1 agonists are potentially useful drugs for treating metabolic dysfunction-associated steatotic liver disease.
    Soresi M; Giannitrapani L
    World J Gastroenterol; 2024 Aug; 30(30):3541-3547. PubMed ID: 39193573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impacts of glucagon-like peptide-1 receptor agonists on the risk of adverse liver outcomes in patients with metabolic dysfunction-associated steatotic liver disease cirrhosis and type 2 diabetes.
    Elsaid MI; Li N; Firkins SA; Rustgi VK; Paskett ED; Acharya C; Reddy KR; Chiang CW; Mumtaz K
    Aliment Pharmacol Ther; 2024 May; 59(9):1096-1110. PubMed ID: 38538967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of transient elastography in diagnosing MAFLD and the early effects of sleeve gastrectomy on MAFLD among the Chinese population.
    Hu R; Wu B; Wang C; Wu Z; Zhang X; Chen X; Lu G; Yuan K
    Int J Surg; 2024 Apr; 110(4):2044-2054. PubMed ID: 38215263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gender Differences in Liver Steatosis and Fibrosis in Overweight and Obese Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease before and after 8 Weeks of Very Low-Calorie Ketogenic Diet.
    Rinaldi R; De Nucci S; Donghia R; Donvito R; Cerabino N; Di Chito M; Penza A; Mongelli FP; Shahini E; Zappimbulso M; Pesole PL; Coletta S; Triggiani V; Cozzolongo R; Giannelli G; De Pergola G
    Nutrients; 2024 May; 16(10):. PubMed ID: 38794646
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of an Eight Week Very Low-Calorie Ketogenic Diet (VLCKD) on White Blood Cell and Platelet Counts in Relation to Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Subjects with Overweight and Obesity.
    De Nucci S; Bonfiglio C; Donvito R; Di Chito M; Cerabino N; Rinaldi R; Sila A; Shahini E; Giannuzzi V; Pesole PL; Coletta S; Lanzilotta E; Piazzolla G; Cozzolongo R; Giannelli G; De Pergola G
    Nutrients; 2023 Oct; 15(20):. PubMed ID: 37892542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Performance of continuous controlled attenuation parameter and liver stiffness measurement by the novel SmartExam in metabolic dysfunction-associated steatotic liver disease.
    Song SJ; Nogami A; Liang LY; Yoneda M; Leung HHW; Nakajima A; Lai JCT; Wong GLH; Shu SST; Wong VWS; Yip TCF
    Liver Int; 2024 May; 44(5):1167-1175. PubMed ID: 38353063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.
    Eddowes PJ; Sasso M; Allison M; Tsochatzis E; Anstee QM; Sheridan D; Guha IN; Cobbold JF; Deeks JJ; Paradis V; Bedossa P; Newsome PN
    Gastroenterology; 2019 May; 156(6):1717-1730. PubMed ID: 30689971
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Usefulness of Transient Elastography for Non-Invasive Diagnosis of Liver Fibrosis in Pediatric Non-Alcoholic Steatohepatitis.
    Kwon YD; Ko KO; Lim JW; Cheon EJ; Song YH; Yoon JM
    J Korean Med Sci; 2019 Jun; 34(23):e165. PubMed ID: 31197983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatic steatosis and not type 2 diabetes, body mass index, or hepatic fibrosis associates with hyperglucagonemia in individuals with steatotic liver disease.
    Kjeldsen SAS; Werge MP; Grandt J; Richter MM; Thing M; Hetland LE; Rashu EB; Jensen AH; Winther-Sørensen M; Kellemann JS; Holst JJ; Junker AE; Serizawa RR; Vyberg M; Gluud LL; Wewer Albrechtsen NJ
    Am J Physiol Gastrointest Liver Physiol; 2024 Oct; 327(4):G558-G570. PubMed ID: 39104323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Applicability and Results of Liver Stiffness Measurement and Controlled Attenuation Parameter Using XL Probe for Metabolic-Associated Fatty Liver Disease in Candidates to Bariatric Surgery. A Single-Center Observational Study.
    Wan T; Köhn N; Kröll D; Berzigotti A
    Obes Surg; 2021 Feb; 31(2):702-711. PubMed ID: 32959331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study.
    Harrison SA; Browne SK; Suschak JJ; Tomah S; Gutierrez JA; Yang J; Roberts MS; Harris MS
    J Hepatol; 2025 Jan; 82(1):7-17. PubMed ID: 39002641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Utility of transient elastography (fibroscan) and impact of bariatric surgery on nonalcoholic fatty liver disease (NAFLD) in morbidly obese patients.
    Garg H; Aggarwal S; Shalimar ; Yadav R; Datta Gupta S; Agarwal L; Agarwal S
    Surg Obes Relat Dis; 2018 Jan; 14(1):81-91. PubMed ID: 29126863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.